CL
ALDX icon

Croft-Leominster’s Aldeyra Therapeutics ALDX Stock Holding History

Croft-Leominster’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-17,000
Closed -$96K – 133
2016
Q2 		$96K Hold
17,000
– – 0.02% 158
2016
Q1 		$71K Buy
+17,000
New +$81.7K 0.02% 162

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Croft-Leominster's ALDX Position: Q3 2016 in Review

Croft-Leominster sold out of Aldeyra Therapeutics (ALDX) in Q3 2016, closing a stake of 17,000 shares — an estimated $96K sold.

Croft-Leominster first reported a position in ALDX in Q1 2016 and held it in 2 quarters. The position peaked at $96K in Q2 2016. 22 funds tracked by Wall St. Rank hold ALDX as of Q3 2016.

  • Croft-Leominster reported no remaining Aldeyra Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Croft-Leominster sold 17,000 Aldeyra Therapeutics shares in Q3 2016, an estimated $96K.
  • Croft-Leominster first reported a position in Aldeyra Therapeutics in Q1 2016 and held it in 2 quarters.
  • Croft-Leominster's Aldeyra Therapeutics position peaked at $96K in Q2 2016.
  • 22 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2016.

Based on Croft-Leominster's 13F filing for Q3 2016, filed 15 Nov 2016.